A5009727912- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Colorectal Cancer Screening and Detection
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Gastrointestinal Bleeding Diagnosis and Treatment
- Tuberculosis Research and Epidemiology
- Pregnancy and Medication Impact
- Mycobacterium research and diagnosis
- Gastric Cancer Management and Outcomes
- Gastrointestinal disorders and treatments
- Diverticular Disease and Complications
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Gastrointestinal motility and disorders
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- IL-33, ST2, and ILC Pathways
- Sphingolipid Metabolism and Signaling
- Colorectal Cancer Surgical Treatments
Lunenfeld-Tanenbaum Research Institute
2021-2025
Sinai Health System
2021-2025
University of Toronto
2021-2025
Mount Sinai Hospital
2021-2025
Sinai Hospital
2023-2025
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2015-2024
Sinai Health System
2023
Sanatorio Otamendi y Miroli
2020
Université de Lorraine
2016-2017
Inserm
2016-2017
Inflammatory bowel disease (IBD) encompasses two major entities: ulcerative colitis (UC) and Crohn's (CD).1 Both are chronic, progressive, disabling conditions that require lifelong medical treatment in most cases. IBD has a impact on the patient's health-related quality of life,2 treatment-related costs place significant burden healthcare systems.3 Historically, management been based use several small-molecule drugs (SMDs), including corticosteroids, immunomodulators (such as azathioprine,...
Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step FC measurement can influence the results, leading misinterpretations and potentially impacting management IBD patients. To date, there high heterogeneity between measurements no current method universally accepted as standard.Our aim was provide clear position statementsabout pre-analytical analytical phases...
Abstract Background Data on real-world therapy outcomes for the use of risankizumab in Crohn’s Disease (CD) remain limited. We aimed to assess effectiveness and safety CD. Methods A retrospective study was carried out at a tertiary referral centre patients started CD between February 2019 November 2024. Primary included: rates clinical response remission weeks 12, 28, 52, endoscopic improvement by week 52. Clinical defined as treatment recorded chart “complete response” or “partial...
Abstract Background For patients with inflammatory bowel diseases (IBD), the ultimate goal is to live a ‘normal life’, yet no validated patient-reported outcome measure (PROM) exists assess this. We aimed develop and validate globally relevant PROM impact of IBD on normal life through world-wide, patient-centred approach, ‘IBD LIFE’. Methods Patients Crohn’s disease (CD) or ulcerative colitis (UC) from Argentina, Australia, India, Netherlands, South Korea, USA without ostomies, pouches,...
Background and Aims: The comparative efficacy of advanced therapies to improve health-related quality life (HR-QoL) in Crohn’s disease (CD) is unknown. We aimed compare the impact approved for moderate-to-severe CD on HR-QoL. Methods: searched MEDLINE, Embase, Cochrane CENTRAL from inception December 2023. included randomized controlled trials (RCTs) that assessed treatment adults with luminal CD. primary outcome was change baseline Inflammatory Bowel Disease Questionnaire (IBDQ). Pairwise...
Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There few published data on persistence IFX ADA CD. We aimed to compare rates versus as first- second-line tumor necrosis factor antagonist (anti-TNF), identify factors potentially associated persistence, evaluate reasons for withdrawal CD patients. performed a retrospective, single-center cohort study treated or at least 6 months between June 2002 May 2016. The median duration...
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians' current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption-whether initiating a biosimilar, transitioning from an or switching between (including multiple switches reverse switching)-a...